High-throughput Screening for p53 Activators
Corresponding Organization : Masaryk University
Other organizations : St. Anne's University Hospital Brno, Czech Academy of Sciences, Institute of Molecular Genetics
Variable analysis
- Library compounds, including the Library of Pharmacologically Active Compounds (LOPAC1280), the Prestwick Chemical Library, and the NIH Clinical Trial Collection
- Doxorubicin (DNA damaging drug)
- Luciferase production
- A375 cells stably transfected with the expression vector pGL4.38 [luc2P/p53 RE/Hygro] using TurboFect
- Cells plated in white 384-well plates at a density of 2,500 cells/25 μl/well
- Cells cultivated overnight before adding compounds
- Cells cultivated for 24 hours after adding compounds
- Luciferase production measured using the One-GLO assay and an EnVision microplate reader
- Positive control: Not explicitly mentioned
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!